Lexicon Pharmaceuticals, INC. (LXRX) — SEC Filings

Overview

Lexicon Pharmaceuticals, INC. (LXRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 6, 2025: On November 6, 2025, Lexicon Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 2 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Lexicon Pharmaceuticals, INC. is neutral.

Filing Type Overview

Lexicon Pharmaceuticals, INC. (LXRX) has filed 23 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13D/A, 3 SC 13G/A, 1 SC 13G with the SEC between Feb 2024 to Nov 2025.

Recent Filings (41)

• 8-K Filing — 8-K · Nov 10, 2025
• Lexicon Pharmaceuticals Files 8-K Report — 8-K · Nov 6, 2025 Risk: low
  On November 6, 2025, Lexicon Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," in
• Lexicon Narrows Losses on Novo Nordisk Deal, Cuts Spending — 10-Q · Nov 6, 2025 Risk: medium
  Lexicon Pharmaceuticals, Inc. reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $34.8 million from $166.6
• Lexicon Pharmaceuticals Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing includes financial stat
• Lexicon's Losses Widen Amid Rising R&D Costs — 10-Q · Aug 6, 2025 Risk: high
  LEXICON PHARMACEUTICALS, INC. reported a net loss of $38.2 million for the three months ended June 30, 2025, a significant increase from the $29.5 million net l
• Lexicon Sells Inhaled Program for $100M — 8-K · Jul 28, 2025 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on July 23, 2025, that it has entered into a definitive agreement to sell its Inhaled Inhaled program, including LX2761,
• Lexicon Pharmaceuticals Files 8-K — 8-K · Jul 3, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on July 3, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the even
• Lexicon Pharmaceuticals Files 8-K on Material Agreement — 8-K · Jun 3, 2025 Risk: medium
  On June 2, 2025, Lexicon Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes information regarding mat
• 10-Q Filing — 10-Q · May 14, 2025
• Lexicon Pharmaceuticals Files 8-K on Financials — 8-K · May 13, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as filing financial statemen
• Lexicon Pharma Details 2024 Executive Compensation — DEF 14A · Apr 22, 2025 Risk: medium
  Lexicon Pharmaceuticals, Inc. filed a DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing inclu
• Lexicon Pharmaceuticals Enters Material Definitive Agreement — 8-K · Mar 28, 2025 Risk: medium
  On March 27, 2025, Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits relate
• 10-K Filing — 10-K · Mar 7, 2025
• Lexicon Pharmaceuticals Files 8-K on Financials — 8-K · Mar 6, 2025 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on March 6, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Lexicon Pharmaceuticals Faces Listing Rule Issues — 8-K · Jan 7, 2025 Risk: high
  Lexicon Pharmaceuticals, Inc. filed an 8-K on January 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a
• Lexicon Pharma Appoints New CMO, Adds Director — 8-K · Jan 2, 2025 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on January 2, 2025, the appointment of Dr. Tamara Joseph as Chief Medical Officer and the election of Ms. Michelle L. Gr
• Invus Group Amends Lexicon Pharma Stake Filing — SC 13D/A · Dec 9, 2024 Risk: medium
  Invus, L.P. and its affiliates have filed a Schedule 13D/A amendment on December 9, 2024, regarding their holdings in Lexicon Pharmaceuticals, Inc. The filing i
• Lexicon Pharma Reports Exit/Disposal Costs — 8-K · Nov 22, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. filed an 8-K on November 22, 2024, to report on costs associated with exit or disposal activities. The filing does not specify the
• Lexicon Pharmaceuticals Appoints New Chief Medical Officer — 8-K · Nov 20, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on November 19, 2024, the appointment of Dr. Tamara A. Z. Joseph as Chief Medical Officer, effective November 20, 2024.
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Lexicon Pharmaceuticals Q3 Expenses Decline — 10-Q · Nov 13, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses of $71.7 million f
• Lexicon Pharmaceuticals Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition, as well as filing financial sta
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Lexicon Pharmaceuticals Enters Material Definitive Agreement — 8-K · Oct 16, 2024 Risk: medium
  On October 16, 2024, Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agree
• Lexicon Pharma Appoints New Chief Medical Officer — 8-K · Sep 16, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on September 13, 2024, the appointment of Dr. Tamara A. P. von Koch as Chief Medical Officer, effective September 16, 20
• 10-Q Filing — 10-Q · Aug 2, 2024
• Lexicon Pharmaceuticals Files 8-K on Financials — 8-K · Aug 1, 2024 Risk: low
  Lexicon Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial stat
• Invus L.P. Amends Lexicon Pharmaceuticals Stake Filing — SC 13D/A · Jul 29, 2024 Risk: medium
  Invus, L.P. filed an amendment to its Schedule 13D on July 29, 2024, regarding its beneficial ownership of Lexicon Pharmaceuticals, Inc. The filing indicates a
• SC 13G Filing — SC 13G · Jul 10, 2024
• Lexicon Pharma Appoints New Chief Medical Officer — 8-K · Jul 8, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on July 3, 2024, the appointment of Dr. Tamara A. Z. Joseph as Chief Medical Officer, effective July 8, 2024. Dr. Joseph
• Lexicon Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jul 1, 2024 Risk: medium
  On June 28, 2024, Lexicon Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement or
• Invus L.P. Amends Lexicon Pharmaceuticals Stake — SC 13D/A · May 14, 2024 Risk: medium
  On May 14, 2024, Invus, L.P. filed an amendment to its Schedule 13D, disclosing its beneficial ownership of Lexicon Pharmaceuticals, Inc. The filing indicates a
• Lexicon Pharmaceuticals Files 8-K with Equity, Bylaw, and Shareholder Votes — 8-K · May 10, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. filed an 8-K on May 10, 2024, reporting on several key events. These include unregistered sales of equity securities, amendments t
• Lexicon Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
  LEXICON PHARMACEUTICALS, INC. (LXRX) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Lexicon Pharmaceuticals, Inc. filed a 10-Q report for the peri
• Lexicon Pharmaceuticals Announces CMO Retirement and Appointment — 8-K · Apr 29, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on April 24, 2024, the retirement of its Chief Medical Officer, Dr. Jeffrey L. Cleary, effective June 30, 2024. Dr. Clea
• Lexicon Pharmaceuticals Announces 2024 Annual Meeting of Stockholders — DEF 14A · Mar 26, 2024 Risk: low
  LEXICON PHARMACEUTICALS, INC. (LXRX) filed a Proxy Statement (DEF 14A) with the SEC on March 26, 2024. The 2024 annual meeting of Lexicon Pharmaceuticals, Inc.
• Lexicon Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  LEXICON PHARMACEUTICALS, INC. (LXRX) filed a Annual Report (10-K) with the SEC on March 25, 2024. Lexicon Pharmaceuticals, Inc. filed its annual report on Form
• Invus L.P. Amends Stake in Lexicon Pharmaceuticals — SC 13D/A · Mar 13, 2024 Risk: medium
  On March 13, 2024, Invus, L.P. filed an amendment to its Schedule 13D, reporting a change in beneficial ownership of Lexicon Pharmaceuticals, Inc. The filing in
• Lexicon Pharmaceuticals Files 8-K on Corporate Changes — 8-K · Mar 12, 2024 Risk: low
  On March 12, 2024, Lexicon Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to the rights of security holders and amendments to its ar
• Lexicon Pharmaceuticals Announces Material Agreement & Financial Updates — 8-K · Mar 11, 2024 Risk: medium
  Lexicon Pharmaceuticals, Inc. announced on March 6, 2024, that it entered into a material definitive agreement. The company also reported its results of operati
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024

Frequently Asked Questions